Simon Lovestone

List of Publications by Citations

178 papers	12,399 citations	50 h-index	109 g-index
247 ext. papers	15,959 ext. citations	7.6 avg, IF	5.53 L-index

#	Paper	IF	Citations
178	Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. *Nature Genetics*, **2013**, 45, 1452-8	36.3	2714
177	Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. *Nature Genetics*, **2019**, 51, 414-430	36.3	917
176	Common genetic variants influence human subcortical brain structures. *Nature*, **2015**, 520, 224-9	50.4	601
175	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. *Nature Genetics*, **2017**, 49, 1373-1384	36.3	508
174	Methylomic profiling implicates cortical deregulation of ANK1 in Alzheimer's disease. *Nature Neuroscience*, **2014**, 17, 1164-70	25.5	356
173	Susceptibility locus for Alzheimer's disease on chromosome 10. *Science*, **2000**, 290, 2304-5	33.3	345
172	A phase II trial of tideglusib in Alzheimer's disease. *Journal of Alzheimers Disease*, **2015**, 45, 75-88	4.3	276
171	Variation in DCP1, encoding ACE, is associated with susceptibility to Alzheimer disease. *Nature Genetics*, **1999**, 21, 71-2	36.3	236
170	Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage. *Brain*, **2015**, 138, 1327-38	11.2	211
169	The future of blood-based biomarkers for Alzheimer's disease. *Alzheimers and Dementia*, **2014**, 10, 115-31	11.2	196
168	Prevention of sporadic Alzheimer's disease: lessons learned from clinical trials and future directions. *Lancet Neurology, The*, **2015**, 14, 926-944	24.1	187
167	Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer's disease research. *Alzheimers and Dementia*, **2015**, 11, 549-60	1.2	159
166	Common brain disorders are associated with heritable patterns of apparent aging of the brain. *Nature Neuroscience*, **2019**, 22, 1617-1623	25.5	157
165	Clusterin regulates β-amyloid toxicity via Dickkopf-1-driven induction of the wnt-PCP-JNK pathway. *Molecular Psychiatry*, **2014**, 19, 88-98	15.1	153
164	Novel genetic loci underlying human intracranial volume identified through genome-wide association. *Nature Neuroscience*, **2016**, 19, 1569-1582	25.5	147
163	Convergent genetic and expression data implicate immunity in Alzheimer's disease. *Alzheimers and Dementia*, **2015**, 11, 658-71	1.2	146
162	AddNeuroMed--the European collaboration for the discovery of novel biomarkers for Alzheimer's disease. *Annals of the New York Academy of Sciences*, **2009**, 1180, 36-46	6.5	140

161	Development of interventions for the secondary prevention of Alzheimer's dementia: the European Prevention of Alzheimer's Dementia (EPAD) project. *Lancet Psychiatry, the*, **2016**, 3, 179-86	23.3	139
160	Plasma proteins predict conversion to dementia from prodromal disease. *Alzheimer's and Dementia*, **2014**, 10, 799-807.e2	1.2	139
159	Alzheimer's disease biomarker discovery using SOMAscan multiplexed protein technology. *Alzheimer's and Dementia*, **2014**, 10, 724-34	1.2	133
158	Antidepressants enhance glucocorticoid receptor function in vitro by modulating the membrane steroid transporters. *British Journal of Pharmacology*, **2001**, 134, 1335-43	8.6	122
157	Developing novel blood-based biomarkers for Alzheimer's disease. *Alzheimer's and Dementia*, **2014**, 10, 109-14	1.2	111
156	NRF2 deficiency replicates transcriptomic changes in Alzheimer's patients and worsens APP and TAU pathology. *Redox Biology*, **2017**, 13, 444-451	11.3	107
155	Clusterin in Alzheimer's Disease: Mechanisms, Genetics, and Lessons From Other Pathologies. *Frontiers in Neuroscience*, **2019**, 13, 164	5.1	106
154	The AddNeuroMed framework for multi-centre MRI assessment of Alzheimer's disease: experience from the first 24 months. *International Journal of Geriatric Psychiatry*, **2011**, 26, 75-82	3.9	106
153	MRI measures of Alzheimer's disease and the AddNeuroMed study. *Annals of the New York Academy of Sciences*, **2009**, 1180, 47-55	6.5	104
152	Cross-region reduction in 5-hydroxymethylcytosine in Alzheimer's disease brain. *Neurobiology of Aging*, **2014**, 35, 1850-4	5.6	96
151	Association of blood lipids with Alzheimer's disease: A comprehensive lipidomics analysis. *Alzheimer's and Dementia*, **2017**, 13, 140-151	1.2	90
150	Gene-wide analysis detects two new susceptibility genes for Alzheimer's disease. *PLoS ONE*, **2014**, 9, e94661	3.7	90
149	Alpha-2 macroglobulin gene and Alzheimer disease. *Nature Genetics*, **1999**, 22, 17-9; author reply 21-2	36.3	88
148	Substantial linkage disequilibrium across the insulin-degrading enzyme locus but no association with late-onset Alzheimer's disease. *Human Genetics*, **2001**, 109, 646-52	6.3	84
147	Circulating Proteomic Signatures of Chronological Age. *Journals of Gerontology - Series A Biological Sciences and Medical Sciences*, **2015**, 70, 809-16	6.4	81
146	Long-term predictors of cognitive outcome in a cohort of older people with hypertension. *British Journal of Psychiatry*, **2000**, 177, 66-71	5.4	81
145	Genetic architecture of subcortical brain structures in 38,851 individuals. *Nature Genetics*, **2019**, 51, 1624-1636	36.3	81
144	Increased plasma neurofilament light chain concentration correlates with severity of post-mortem neurofibrillary tangle pathology and neurodegeneration. *Acta Neuropathologica Communications*, **2019**, 7, 5	7.3	79

143   Sites of phosphorylation in tau and factors affecting their regulation. *Biochemical Society Symposia*, **2001**, 67, 73-80   79

142   Mitochondrial genes are altered in blood early in Alzheimer's disease. *Neurobiology of Aging*, **2017**, 53, 36-47   5.6   78

141   The effect of increased genetic risk for Alzheimer's disease on hippocampal and amygdala volume. *Neurobiology of Aging*, **2016**, 40, 68-77   5.6   78

140   Blood-Based Proteomic Biomarkers of Alzheimer's Disease Pathology. *Frontiers in Neurology*, **2015**, 6, 236   4.1   77

139   Inflammatory biomarkers in Alzheimer's disease plasma. *Alzheimer's and Dementia*, **2019**, 15, 776-787   1.2   74

138   Elevated DNA methylation across a 48-kb region spanning the HOXA gene cluster is associated with Alzheimer's disease neuropathology. *Alzheimer's and Dementia*, **2018**, 14, 1580-1588   1.2   73

137   Identification of cis-regulatory variation influencing protein abundance levels in human plasma. *Human Molecular Genetics*, **2012**, 21, 3719-26   5.6   71

136   Development and Application of Ultra-Performance Liquid Chromatography-TOF MS for Precision Large Scale Urinary Metabolic Phenotyping. *Analytical Chemistry*, **2016**, 88, 9004-13   7.8   71

135   Genetic predisposition to increased blood cholesterol and triglyceride lipid levels and risk of Alzheimer disease: a Mendelian randomization analysis. *PLoS Medicine*, **2014**, 11, e1001713   11.6   62

134   Minocycline at 2 Different Dosages vs Placebo for Patients With Mild Alzheimer Disease: A Randomized Clinical Trial. *JAMA Neurology*, **2020**, 77, 164-174   17.2   62

133   A Decade of Blood Biomarkers for Alzheimer's Disease Research: An Evolving Field, Improving Study Designs, and the Challenge of Replication. *Journal of Alzheimer's Disease*, **2018**, 62, 1181-1198   4.3   62

132   Crowdsourced estimation of cognitive decline and resilience in Alzheimer's disease. *Alzheimer's and Dementia*, **2016**, 12, 645-53   1.2   58

131   Disturbance of Notch-1 and Wnt signalling proteins in neuroglial balloon cells and abnormal large neurons in focal cortical dysplasia in human cortex. *Acta Neuropathologica*, **1999**, 98, 465-72   14.3   55

130   Automated Hippocampal Subfield Measures as Predictors of Conversion from Mild Cognitive Impairment to Alzheimer's Disease in Two Independent Cohorts. *Brain Topography*, **2015**, 28, 746-759   4.3   54

129   Heterogeneous patterns of brain atrophy in Alzheimer's disease. *Neurobiology of Aging*, **2018**, 65, 98-108   5.6   52

128   Amyloid βsynaptotoxicity is Wnt-PCP dependent and blocked by fasudil. *Alzheimer's and Dementia*, **2018**, 14, 306-317   1.2   46

127   Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study. *Lancet Neurology, The*, **2019**, 18, 1034-1044   24.1   45

126   A plasma protein classifier for predicting amyloid burden for preclinical Alzheimer's disease. *Science Advances*, **2019**, 5, eaau7220   14.3   44

125	Alzheimer's disease in humans and other animals: A consequence of postreproductive life span and longevity rather than aging. *Alzheimer's and Dementia*, **2018**, 14, 195-204	1.2	44
124	PET Tau and Amyloid-Burden in Mild Alzheimer's Disease: Divergent Relationship with Age, Cognition, and Cerebrospinal Fluid Biomarkers. *Journal of Alzheimer's Disease*, **2017**, 60, 283-293	4.3	44
123	Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer's disease. *Alzheimer's Research and Therapy*, **2019**, 11, 26	9	43
122	Targeted neurogenesis pathway-based gene analysis identifies ADORA2A associated with hippocampal volume in mild cognitive impairment and Alzheimer's disease. *Neurobiology of Aging*, **2017**, 60, 92-103	5.6	42
121	Association between Plasma Ceramides and Phosphatidylcholines and Hippocampal Brain Volume in Late Onset Alzheimer's Disease. *Journal of Alzheimer's Disease*, **2017**, 60, 809-817	4.3	40
120	Blood Protein Markers of Neocortical Amyloid-Burden: A Candidate Study Using SOMAscan Technology. *Journal of Alzheimer's Disease*, **2015**, 46, 947-61	4.3	40
119	Proteomics of Alzheimer's disease: understanding mechanisms and seeking biomarkers. *Expert Review of Proteomics*, **2007**, 4, 227-38	4.2	40
118	Design, synthesis and evaluation in an LPS rodent model of neuroinflammation of a novel F-labelled PET tracer targeting P2X7. *EJNMMI Research*, **2017**, 7, 31	3.6	39
117	Stimulation of MAP kinase by v-raf transformation of fibroblasts fails to induce hyperphosphorylation of transfected tau. *FEBS Letters*, **1995**, 365, 42-6	3.8	38
116	Predictors of care home and hospital admissions and their costs for older people with Alzheimer's disease: findings from a large London case register. *BMJ Open*, **2016**, 6, e013591	3	38
115	Blood protein predictors of brain amyloid for enrichment in clinical trials?. *Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2015**, 1, 48-60	5.2	37
114	The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer's disease. *Alzheimer's Research and Therapy*, **2017**, 9, 85	9	36
113	The midlife cognitive profiles of adults at high risk of late-onset Alzheimer's disease: The PREVENT study. *Alzheimer's and Dementia*, **2017**, 13, 1089-1097	1.2	35
112	No association of salivary total tau concentration with Alzheimer's disease. *Neurobiology of Aging*, **2018**, 70, 125-127	5.6	35
111	No differences in hippocampal volume between carriers and non-carriers of the ApoE 4 and 2 alleles in young healthy adolescents. *Journal of Alzheimer's Disease*, **2014**, 40, 37-43	4.3	35
110	Comparing biological markers of Alzheimer's disease across blood fraction and platforms: Comparing apples to oranges. *Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2016**, 3, 27-34	5.2	35
109	Protective effect of antirheumatic drugs on dementia in rheumatoid arthritis patients. *Alzheimer's and Dementia: Translational Research and Clinical Interventions*, **2017**, 3, 612-621	6	33
108	Complement Biomarkers as Predictors of Disease Progression in Alzheimer's Disease. *Journal of Alzheimer's Disease*, **2016**, 54, 707-16	4.3	33

107	Effects of FTDP-17 mutations on the in vitro phosphorylation of tau by glycogen synthase kinase 3beta identified by mass spectrometry demonstrate certain mutations exert long-range conformational changes. *FEBS Letters*, **2001**, 493, 40-4	3.8	31
106	Blood-Based Biomarker Candidates of Cerebral Amyloid Using PiB PET in Non-Demented Elderly. *Journal of Alzheimer's Disease*, **2016**, 52, 561-72	4.3	31
105	Commonly prescribed drugs associate with cognitive function: a cross-sectional study in UK Biobank. *BMJ Open*, **2016**, 6, e012177	3	31
104	Cross-sectional and longitudinal analyses of outdoor air pollution exposure and cognitive function in UK Biobank. *Scientific Reports*, **2018**, 8, 12089	4.9	30
103	CERAD neuropsychological compound scores are accurate in detecting prodromal alzheimer's disease: a prospective AddNeuroMed study. *Journal of Alzheimer's Disease*, **2014**, 39, 679-90	4.3	30
102	Gait in Mild Alzheimer's Disease: Feasibility of Multi-Center Measurement in the Clinic and Home with Body-Worn Sensors: A Pilot Study. *Journal of Alzheimer's Disease*, **2018**, 63, 331-341	4.3	29
101	Quantitative validation of a visual rating scale for frontal atrophy: associations with clinical status, APOE e4, CSF biomarkers and cognition. *European Radiology*, **2016**, 26, 2597-610	8	29
100	A metabolite-based machine learning approach to diagnose Alzheimer-type dementia in blood: Results from the European Medical Information Framework for Alzheimer disease biomarker discovery cohort. *Alzheimer's and Dementia: Translational Research and Clinical Interventions*, **2019**, 5, 933-938	6	29
99	Advanced glycation end products, dementia, and diabetes. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, 4743-4	11.5	28
98	The influence of insulin resistance on cerebrospinal fluid and plasma biomarkers of Alzheimer's pathology. *Alzheimer's Research and Therapy*, **2017**, 9, 31	9	27
97	Red blood cell indices and anaemia as causative factors for cognitive function deficits and for Alzheimer's disease. *Genome Medicine*, **2018**, 10, 51	14.4	27
96	Developing a new model for patient recruitment in mental health services: a cohort study using Electronic Health Records. *BMJ Open*, **2014**, 4, e005654	3	27
95	The Effect of Age Correction on Multivariate Classification in Alzheimer's Disease, with a Focus on the Characteristics of Incorrectly and Correctly Classified Subjects. *Brain Topography*, **2016**, 29, 296-307	4.3	27
94	Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort. *Alzheimer's and Dementia*, **2019**, 15, 817-827	1.2	26
93	Glycosylation of Human Plasma Clusterin Yields a Novel Candidate Biomarker of Alzheimer's Disease. *Journal of Proteome Research*, **2015**, 14, 5063-76	5.6	26
92	The reliability of a deep learning model in clinical out-of-distribution MRI data: A multicohort study. *Medical Image Analysis*, **2020**, 66, 101714	15.4	26
91	Generalizability of the disease state index prediction model for identifying patients progressing from mild cognitive impairment to Alzheimer's disease. *Journal of Alzheimer's Disease*, **2015**, 44, 79-92	4.3	26
90	A Pathway Based Classification Method for Analyzing Gene Expression for Alzheimer's Disease Diagnosis. *Journal of Alzheimer's Disease*, **2016**, 49, 659-69	4.3	26

89	A Multi-Cohort Study of ApoE e4 and Amyloid-β Effects on the Hippocampus in Alzheimer's Disease. *Journal of Alzheimer's Disease*, **2017**, 56, 1159-1174	4.3	25
88	Clusterin Is Required for β Amyloid Toxicity in Human iPSC-Derived Neurons. *Frontiers in Neuroscience*, **2018**, 12, 504	5.1	25
87	Longitudinal Protein Changes in Blood Plasma Associated with the Rate of Cognitive Decline in Alzheimer's Disease. *Journal of Alzheimer's Disease*, **2016**, 49, 1105-14	4.3	24
86	Down syndrome with and without dementia: an in vivo proton Magnetic Resonance Spectroscopy study with implications for Alzheimer's disease. *NeuroImage*, **2011**, 57, 63-68	7.9	24
85	The Notch intracellular domain represses CRE-dependent transcription. *Cellular Signalling*, **2015**, 27, 621-9	4.9	23
84	Application of a MRI based index to longitudinal atrophy change in Alzheimer disease, mild cognitive impairment and healthy older individuals in the AddNeuroMed cohort. *Frontiers in Aging Neuroscience*, **2014**, 6, 145	5.3	23
83	Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay. *Alzheimer's and Dementia*, **2019**, 15, 1478-1488	1.2	22
82	Precompetitive Data Sharing as a Catalyst to Address Unmet Needs in Parkinson's Disease. *Journal of Parkinson's Disease*, **2015**, 5, 581-94	5.3	22
81	Metabolic phenotyping reveals a reduction in the bioavailability of serotonin and kynurenine pathway metabolites in both the urine and serum of individuals living with Alzheimer's disease. *Alzheimer's Research and Therapy*, **2021**, 13, 20	9	22
80	Early diagnosis and the clinical genetics of Alzheimer's disease. *Journal of Neurology*, **1999**, 246, 69-72	5.5	21
79	The role of the father in parental postnatal mental health. *The British Journal of Medical Psychology*, **1995**, 68 (Pt 2), 157-68		21
78	Apolipoprotein e genotype and late paraphrenia. *International Journal of Geriatric Psychiatry*, **1995**, 10, 147-150	3.9	21
77	A Subset of Cerebrospinal Fluid Proteins from a Multi-Analyte Panel Associated with Brain Atrophy, Disease Classification and Prediction in Alzheimer's Disease. *PLoS ONE*, **2015**, 10, e0134368	3.7	21
76	Differential effects of apolipoprotein E isoforms on phosphorylation at specific sites on tau by glycogen synthase kinase-3 beta identified by nano-electrospray mass spectrometry. *FEBS Letters*, **2000**, 485, 99-103	3.8	20
75	Plasma Protein Biomarkers for the Prediction of CSF Amyloid and Tau and [F]-Flutemetamol PET Scan Result. *Frontiers in Aging Neuroscience*, **2018**, 10, 409	5.3	20
74	The human brainome: network analysis identifies HSPA2 as a novel Alzheimer's disease target. *Brain*, **2018**, 141, 2721-2739	11.2	19
73	The interactive effect of demographic and clinical factors on hippocampal volume: A multicohort study on 1958 cognitively normal individuals. *Hippocampus*, **2017**, 27, 653-667	3.5	18
72	Are premorbid abnormal personality traits associated with behavioural and psychological symptoms in dementia?. *International Journal of Geriatric Psychiatry*, **2016**, 31, 1050-5	3.9	18

71	Stability of graph theoretical measures in structural brain networks in Alzheimer's disease. *Scientific Reports*, **2018**, 8, 11592	4.9	18
70	An epigenome-wide association study of Alzheimer's disease blood highlights robust DNA hypermethylation in the HOXB6 gene. *Neurobiology of Aging*, **2020**, 95, 26-45	5.6	17
69	Genetic and Real-World Clinical Data, Combined with Empirical Validation, Nominate Jak-Stat Signaling as a Target for Alzheimer's Disease Therapeutic Development. *Cells*, **2019**, 8,	7.9	15
68	Boosting translational research on Alzheimer's disease in Europe: The Innovative Medicine Initiative AD research platform. *Alzheimer's and Dementia*, **2015**, 11, 1121-2	1.2	14
67	Differences in cohort study data affect external validation of artificial intelligence models for predictive diagnostics of dementia - lessons for translation into clinical practice. *EPMA Journal*, **2020**, 11, 367-376	8.8	14
66	APOE ε4 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer's disease. *Alzheimer's Research and Therapy*, **2020**, 12, 65	9	13
65	Aβ42/Aβ40 and Aβ42/Aβ38 Ratios Are Associated with Measures of Gait Variability and Activities of Daily Living in Mild Alzheimer's Disease: A Pilot Study. *Journal of Alzheimer's Disease*, **2018**, 65, 1377-1383	4.3	13
64	Tackling gaps in developing life-changing treatments for dementia. *Alzheimer's and Dementia: Translational Research and Clinical Interventions*, **2019**, 5, 241-253	6	11
63	Tract Based Spatial Statistic Reveals No Differences in White Matter Microstructural Organization between Carriers and Non-Carriers of the APOE e4 and e2 Alleles in Young Healthy Adolescents. *Journal of Alzheimer's Disease*, **2015**, 47, 977-84	4.3	11
62	UK Alzheimer's disease genetics consortium. *International Journal of Geriatric Psychiatry*, **1999**, 14, 789-91	3.9	11
61	A call for comparative effectiveness research to learn whether routine clinical care decisions can protect from dementia and cognitive decline. *Alzheimer's Research and Therapy*, **2016**, 8, 33	9	11
60	Urinary metabolic phenotyping for Alzheimer's disease. *Scientific Reports*, **2020**, 10, 21745	4.9	10
59	Validation of Plasma Proteomic Biomarkers Relating to Brain Amyloid Burden in the EMIF-Alzheimer's Disease Multimodal Biomarker Discovery Cohort. *Journal of Alzheimer's Disease*, **2020**, 74, 213-225	4.3	10
58	Imaging Aβ and tau in early stage Alzheimer's disease with [F]AV45 and [F]AV1451. *EJNMMI Research*, **2018**, 8, 19	3.6	10
57	Genome-wide association study of Alzheimer's disease CSF biomarkers in the EMIF-AD Multimodal Biomarker Discovery dataset. *Translational Psychiatry*, **2020**, 10, 403	8.6	10
56	Determining the Molecular Pathways Underlying the Protective Effect of Non-Steroidal Anti-Inflammatory Drugs for Alzheimer's Disease: A Bioinformatics Approach. *Computational and Structural Biotechnology Journal*, **2017**, 15, 1-7	6.8	9
55	Effects of freezer storage time on levels of complement biomarkers. *BMC Research Notes*, **2017**, 10, 559	2.3	9
54	Linking Genetics of Brain Changes to Alzheimer's Disease: Sparse Whole Genome Association Scan of Regional MRI Volumes in the ADNI and AddNeuroMed Cohorts. *Journal of Alzheimer's Disease*, **2015**, 45, 851-64	4.3	9

53	Tau pathology in early Alzheimer's disease is linked to selective disruptions in neurophysiological network dynamics. *Neurobiology of Aging*, **2020**, 92, 141-152	5.6	8
52	Alleles that increase risk for type 2 diabetes mellitus are not associated with increased risk for Alzheimer's disease. *Neurobiology of Aging*, **2014**, 35, 2883.e3-2883.e10	5.6	8
51	Hippocampal glutamate-glutamine (Glx) in adults with Down syndrome: a preliminary study using in vivo proton magnetic resonance spectroscopy ((1)H MRS). *Journal of Neurodevelopmental Disorders*, **2014**, 6, 42	4.6	8
50	Genome-wide transcriptome analysis identifies novel dysregulated genes implicated in Alzheimer's pathology. *Alzheimer's and Dementia*, **2020**, 16, 1213-1223	1.2	8
49	No Genetic Overlap Between Circulating Iron Levels and Alzheimer's Disease. *Journal of Alzheimer's Disease*, **2017**, 59, 85-99	4.3	7
48	Differential Associations of IL-4 With Hippocampal Subfields in Mild Cognitive Impairment and Alzheimer's Disease. *Frontiers in Aging Neuroscience*, **2018**, 10, 439	5.3	7
47	Recruitment, Retainment, and Biomarkers of Response; A Pilot Trial of Lithium in Humans With Mild Cognitive Impairment. *Frontiers in Molecular Neuroscience*, **2019**, 12, 163	6.1	6
46	Editorial Review. The genetics of Alzheimer's disease: new opportunities and new challenges. *International Journal of Geriatric Psychiatry*, **1996**, 11, 491-497	3.9	6
45	Minocycline 200 mg or 400 mg versus placebo for mild Alzheimer's disease: the MADE Phase II, three-arm RCT. *Efficacy and Mechanism Evaluation*, **2020**, 7, 1-62	1.7	6
44	Dysregulated Fc gamma receptor-mediated phagocytosis pathway in Alzheimer's disease: network-based gene expression analysis. *Neurobiology of Aging*, **2020**, 88, 24-32	5.6	6
43	Meta-analysis of genome-wide DNA methylation identifies shared associations across neurodegenerative disorders. *Genome Biology*, **2021**, 22, 90	18.3	6
42	Deep and Frequent Phenotyping study protocol: an observational study in prodromal Alzheimer's disease. *BMJ Open*, **2019**, 9, e024498	3	5
41	Acetylcholinesterase treatment--modelling potential demand and auditing practice. *International Journal of Geriatric Psychiatry*, **2001**, 16, 1136-42	3.9	5
40	A genetic test for Alzheimer's disease?. *Psychiatric Bulletin*, **1994**, 18, 645-645		5
39	Methotrexate and relative risk of dementia amongst patients with rheumatoid arthritis: a multi-national multi-database case-control study. *Alzheimer's Research and Therapy*, **2020**, 12, 38	9	5
38	ANMerge: A Comprehensive and Accessible Alzheimer's Disease Patient-Level Dataset. *Journal of Alzheimer's Disease*, **2021**, 79, 423-431	4.3	5
37	Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimer's Disease Pathology. *Journal of Alzheimer's Disease*, **2020**, 77, 1353-1368	4.3	4
36	Replication study of plasma proteins relating to Alzheimer's pathology. *Alzheimer's and Dementia*, **2021**, 17, 1452-1464	1.2	4

35	TMEM106B and CPOX are genetic determinants of cerebrospinal fluid Alzheimer's disease biomarker levels. *Alzheimer's and Dementia*, **2021**, 17, 1628-1640	1.2	4
34	Blood biomarkers for Alzheimer's disease. *Genome Medicine*, **2014**, 6, 65	14.4	3
33	Association of blood-based transcriptional risk scores with biomarkers for Alzheimer disease. *Neurology: Genetics*, **2020**, 6, e517	3.8	3
32	Plasma Proteomic Biomarkers Relating to Alzheimer's Disease: A Meta-Analysis Based on Our Own Studies. *Frontiers in Aging Neuroscience*, **2021**, 13, 712545	5.3	3
31	[P4033]: DEEP AND FREQUENT PHENOTYPING: A FEASIBILITY STUDY FOR EXPERIMENTAL MEDICINE IN DEMENTIA **2017**, 13, P1268-P1269		2
30	No Evidence to Suggest that the Use of Acetylcholinesterase Inhibitors Confounds the Results of Two Blood-Based Biomarker Studies in Alzheimer's Disease. *Journal of Alzheimer's Disease*, **2015**, 47, 741-50	4.3	2
29	Genetics, molecular biology, neuropathology and phenotype of frontal lobe dementia: a case history. *British Journal of Psychiatry*, **2002**, 180, 455-60	5.4	2
28	A missense variant in SHARPIN mediates Alzheimer's disease-specific brain damages. *Translational Psychiatry*, **2021**, 11, 590	8.6	2
27	[P2012]: EUROPEAN MEDICAL INFORMATION FRAMEWORK FOR ALZHEIMER's DISEASE (EMIF-AD): THE BIOMARKER DISCOVERY STUDY **2017**, 13, P691-P692		1
26	Trait, state, and mechanism: looking back, looking forward, and understanding why. *Journal of Alzheimer's Disease*, **2013**, 33 Suppl 1, S23-33	4.3	1
25	Biomarkers in brain disease. Preface. *Annals of the New York Academy of Sciences*, **2009**, 1180, vii	6.5	1
24	Muscarinic therapies in Alzheimer's disease; from palliative treatments to disease modification. *International Journal of Psychiatry in Clinical Practice*, **1997**, 1, 15-20	2.4	1
23	ANMerge: A comprehensive and accessible Alzheimer's disease patient-level dataset		1
22	Headache and type 2 diabetes association: a US national ambulatory case-control study		1
21	Comorbidity between Alzheimer's disease and major depression: a behavioural and transcriptomic characterization study in mice. *Alzheimer's Research and Therapy*, **2021**, 13, 73	9	1
20	Serum from Older Adults Increases Apoptosis and Molecular Aging Markers in Human Hippocampal Progenitor Cells **2021**, 12, 2151-2172		0
19	Genome-Wide Association Study of Alzheimer's Disease Brain Imaging Biomarkers and Neuropsychological Phenotypes in the European Medical Information Framework for Alzheimer's Disease Multimodal Biomarker Discovery Dataset.. *Frontiers in Aging Neuroscience*, **2022**, 14, 840651	5.3	0
18	P3-113: NOVEL CANDIDATE BLOOD PROTEOME MARKERS OF ALZHEIMER'S DISEASE BRAIN AMYLOID BURDEN: A MULTIPLEX TMT-LC/MS-MS DISCOVERY APPROACH **2014**, 10, P669-P670		

17   O3-04-03: CROSS-TISSUE METHYLOMIC PROFILING IN ALZHEIMER'S DISEASE **2014**, 10, P215-P215

16   [P4130]: βAMYLOID SYNAPTOTOXICITY DRIVES βAMYLOID PRODUCTION **2017**, 13, P1306-P1306

15   [P1027]: PET TAU AND AMYLOID-BETA DIFFER IN THEIR RELATIONSHIP TO AGE, COGNITION AND CSF BIOMARKERS IN MILD ALZHEIMER's DISEASE: AN OBSERVATIONAL STUDY **2017**, 13, P243

14   [P3051]: COULD COMPLEMENT INHIBITION BE A GOOD THERAPEUTIC TARGET IN ALZHEIMER's DISEASE? **2017**, 13, P950

13   [P4026]: BEST COMBINATORIAL LOW-COST MARKERS TO PREDICT MCI CONVERSION: AN EMIF-AD FEDERATION STUDY **2017**, 13, P1356-P1357

12   [P1448]: PET TAU AND AMYLOID-BETA DIFFER IN THEIR RELATIONSHIP TO AGE, COGNITION AND CSF BIOMARKERS IN MILD ALZHEIMER's DISEASE: AN OBSERVATIONAL STUDY **2017**, 13, P456-P457

11   [P2023]: MARKERS OF CIRCADIAN CLOCK FUNCTION IN ALZHEIMER's DISEASE **2017**, 13, P696-P696

10   [F1202]: DISCOVERY AND VALIDATION OF MULTIMODAL BIOMARKER SIGNATURES RELATING TO ALZHEIMER'S DISEASE PATHOLOGY AND PROGRESSION **2017**, 13, P174-P175

9   O2-05-01: Clusterin, an amyloid chaperone protein in plasma is associated with longitudinal brain atrophy in mild cognitive impairment **2010**, 6, S106-S107

8   Neurogenetics: Scientific and Clinical Advances (Series: Neurological Disease and Therapy, Volume 75) Editor: DAVID R. LYNCH New York: Taylor & Francis, 2006, US$198.95 Hardback, 755 pp. ISBN 0 8247 2942 0. *International Psychogeriatrics*, **2007**, 19, 337   3.4

7   Neurogenetics: Scientific and Clinical Advances (Series: Neurological Disease and Therapy, Volume 75) Editor: DAVID R. LYNCH New York: Taylor & Francis, 2006, US$198.95 Hardback, 755 pp. ISBN 0 8247 2942 0. *International Psychogeriatrics*, **2006**, 1   3.4

6   Possible Future Treatments and Preventative Strategies for Alzheimer's Disease325-326

5   Biological Research on Dementias287-322

4   It takes Tau to tangle. *International Journal of Geriatric Psychiatry*, **1996**, 11, 363-368   3.9

3   Long life or old age? (Working with the elderly). *Psychiatric Bulletin*, **1992**, 16, 168-168

2   Neurodegenerative Disorders - Mechanisms and Prospects for Therapy. Edited by D. L. Price, H. Thoenen and A. J. Aguayo Chichester: John Wiley & Sons. 1991. 301 pp. £50.00.. *British Journal of Psychiatry*, **1993**, 162, 294-294   5.4

1   Better together for better dementia research and care. *Lancet Psychiatry,the*, **2016**, 3, 503-4   23.3